Open to Enrollment Studies

KRH Default

Cancer

To learn more or enroll in the following studies, contact Glacier View Research Institute-Cancer.

BREAST CANCER COLLABORATIVE REGISTRY
An investigator-initiated, multisite institutional, noninterventional trial sponsored by the University of Nebraska Medical Center. The registry is focused on the collection of detailed information of participants to help create a resource that will be helpful to researchers in future studies related to breast cancer. It is the hope that future research using information from this registry will lead to improved diagnosis, prevention and treatment of breast cancers.
Principal investigator: Melissa Hulvat, MD

INCYTE MOST REGISTRY
A prospective, longitudinal, noninterventional study of disease burden and treatment of patients with low-risk myelofibrosis or high-risk essential thrombocythemia (ET) or ET patients receiving ET-directed therapy.
Principal investigator: Elise Anderes, MD

MERCK KEYNOTE 407
MK-3475-407-00
A randomized, double-blind, phase III study of carboplatin-paclitaxel/nab-paclitaxel chemotherapy with or without pembrolizumab (MK-3475) in first line metastatic squamous non-small cell lung cancer subjects.
Principal investigator: Elise Anderes, MD

MIRACA REGISTRY
A registry of hematopoietic disease for evaluation and correlation with clinical outcomes.
Principal investigator: Peter Wagner, MD

MONTANA CANCER CONSORTIUM TRIALS
The Montana Cancer Consortium is a NCI Community Oncology Research Program (NCORP) that gives patients at Kalispell Regional Healthcare access to more than 80 clinical trials for various disease sites, including brain, breast, lung, gastrointestinal, genitourinary, gynecological, lymphomas, melanoma, multiple myeloma and neuroendocrine diseases. These trials are sponsored by cooperative groups in the U.S. (i.e., ALLIANCE, ECOG-ACRIN, NRG, SWOG) and the National Cancer Institute (NCI). This includes cancer prevention clinical trials and cancer care delivery research (CCDR). For more information on the current trials, visit mtcancer.org.

NOVARTIS CLEE011G2301 (EARLEE-1)
A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high-risk early breast cancer.
Principal investigator: Ryan Roop, MD

Cardiology

To learn more or enroll in the following studies, contact Glacier View Research Institute-Cardiology.

AEGIS II
Patients who present to the ER with an ACS event. Patients will be randomized to CSL112/or placebo infusions. CSL112 is a novel compound formulated to deliver exogenous apoA-I via transfusion, thereby removing excess cholesterol from arteries containing atherosclerotic plaques and transport back to the liver for excretion. Patients will receive 4 weekly infusions and followed for one year.
Principal investigator: Eve Gillespie, MD
Sponsor: CSL Behring
Contact: Pat Keane-Richmond, RN, CCRC, at (406) 257-8992 ext 2246 or pkeane@krmc.org and Lucia Kufa, MS, CCRC, at (406) 257-8992 ext 2230 orlkufa@krmc.org

ARTESIA
A study for patients with implanted devices which may record episodes of atrial fibrillation with durations of six minutes to 24 hours. Patients will be randomized to ASA or apixaban, and monitored for two years.
Principal investigator: Eve Gillespie, MD
Sponsor: Hamilton Health Sciences
Contact: Pat Keane-Richmond, RN, CCRC, at (406) 257-8992, ext 2246 or pkeane@krmc.org or Lucia Kufa, MS, CCRC, (406) 257-8992, ext 2230 or lkufa@krmc.org

PLEXA REGISTRY
To confirm the long-term safety and reliability of Biotronik's Plexa lead, as used in conjunction with a U.S. market released Biotronik implantable cardioverter defibrillator or cardiac resynchronization therapy defibrillator pulse generator. The evaluation of safety will be based on the analysis of Plexa lead failures contributing to loss of bradycardia pacing or shock therapy. Additionally, acute and chronic Plexa lead parameters will be evaluated.
Principal investigator: Matt Brunson, MD
Sponsor: Biotronik
Contact: Pat Keane-Richmond, RN, CCRC, at (406) 257-8992, ext 2246 or pkeane@krmc.org, or Lucia Kufa, MS, CCRC, at (406) 257-8992 ext. 2230 or lkufa@krmc.org

QP EXCELS
Confirm long-term safety of the Biotronik Sentus OTW QP left ventricular pacing leads. The evaluation of safety will be freedom from Sentus QP related complications at five years post-implant.
Principal investigator: Matt Brunson, MD
Sponsor: Biotronik
Contact: Pat Keane-Richmond, RN, CCRC, at (406) 257-8992, ext 2246 or pkeane@krmc.org, or Lucia Kufa, MS, CCRC, at (406) 257-8992 ext. 2230 or lkufa@krmc.org

BIOLIBRA: 
Device registry for non-ischemic cardiomyopathies. Special attention to enrolling females.
Principal investigator: Matt Brunson, MD 
Sponsor:
 BIOTRONIC 
Contacts: Pat Keane-Richmond, RN, CCRC, at (406) 257-8992 ext 2246 or pkeane@krmc.org, or Lucia Kufa, MS, CCRC at (406) 257-8992 ext. 2230 or lkufa@krmc.org.

METEORIC-HF: 
HFrEF trial testing OMECAMTIV MECARBIL in stable, symptomatic heart failure patients. Involves Cardio-Pulmonary testing, activitiy monitoring to assess improvement in heart failure symptoms. 
Principal investigator: Dr Eve Gillespie 
Sponsor:  Cytokinetics 
Contact: Pat Keane-Richmond, RN, CCRC, at (406) 257-8992 ext 2246 or pkeane@krmc.org, or Lucia Kufa, MS, CCRC at (406) 257-8992 ext. 2230 or lkufa@krmc.org.

SPRINT-IPF: 
For patients with Interstitial Pulmonary Fibrosis on stable dose of OFEV. Activity monitoring, subjective activity diary questionnaires, exercise substudy for those that qualify. Subjects will be randomized to Pulmonary Rehab or standard of care. 
Principal investigator: Dr Tim Obermiller. 
Sponsor:  Boehringer Ingelheim 
Contact: Pat Keane-Richmond, RN, CCRC, at (406) 257-8992 ext 2246 or pkeane@krmc.org, or Lucia Kufa, MS, CCRC at (406) 257-8992 ext. 2230 or lkufa@krmc.org.

Endocrinology

To learn more or enroll in the following studies, contact Glacier View Research Institute-Endocrinology.

PROMINENT
Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes.
Principal investigator: Jose de Souza, MD
 
NN4419
Comparing the effect of insulin degludec and insulin glargine with or without OADs in subjects with type 2 diabetes using flash glucose monitoring.
Principal Investigator: Jose de Souza, MD

Surpass
To evaluate the efficacy and safety of LY3298176 once weekly injection versus  a daily injection of Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk.
Principal Investigator: Jose de Souza, MD
 
Gazelle
An open label study comparing the safety and efficacy of MYL-1601D with Novolog in Type 1 Diabetes Patients.
Principal Investigator: Jose de Souza, MD
 
Rhythm
Identify individuals with rare genetic disorders of obesity.
 

Rheumatology

To learn more or enroll in the following studies, contact Glacier View Research Institute-Rheumatology.

Eli Lilly I4V-MC-JAJA
A Phase 3b/4, Randomized, Active-Controlled, Parallel-Group Study of Baricitinib in Patients with Rheumatoid Arthritis- RA BRIDGE
Principal investigator: Roger Diegel, MD 
Contract Jaime Wyatt at (406) 755-1460 or jwyatt@krmc.org 

AbbVie M15-998
A Phase 3 Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(ies)
Principal investigator: Roger Diegel, MD 
Contract Jaime Wyatt at (406) 755-1460 or jwyatt@krmc.org 

Eli Lilly I4V-MC-JAIA
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Outpatient, 52-Week Study Evaluating the Efficacy and Safety of Baricitinib 2mg and 4mg in Patients with SLE Receiving Standard Therapy
Principal investigator: Roger Diegel, MD 
Contract Jaime Wyatt at (406) 755-1460 or jwyatt@krmc.org

AbbVie M16-011
A Phase 3 Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Principal investigator: Roger Diegel, MD 
Contract Jaime Wyatt at (406) 755-1460 or jwyatt@krmc.org